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doi:10.1016/j.kjms.2011.03.008Abstract Vascular endothelial growth factor (VEGF), angiopoietin-2, and endostatin have
been reported to be related with angiogenesis of hepatocellular carcinoma (HCC). The poten-
tial feasibility of serial serum VEGF-A, angiopoietin-2, and endostatin measurements in
cirrhotic patients with HCC treated by transcatheter arterial chemoembolization (TACE) was
investigated. VEGF-A, angiopoietin-2, and endostatin serum level were determined by
enzyme-linked immunosorbent assay 1 day before and 7 days after TACE in 40 patients. Then
they were followed up for 3 months. The results showed that TACE could cause significant
increase of VEGF-A (p < 0.01) and angiopoietin-2 (pZ 0.01); whereas there was no significant
change of endostatin (p > 0.1). Twenty-five patients with rapid growth of HCC within 3 months
after TACE had higher proportion of American Joint Committee on Cancer HCC staging >II and
higher increase of VEGF-A after TACE than 15 patients without rapid growth (all p < 0.05).
Stepwise logistic regression analysis revealed that VEGF-A >16.7 pg/mL 7 days after TACE
selected by receiver operating characteristic curve analysis (p < 0.05) was the only indepen-
dent predictor for rapid growth of HCC (odds ratio 6.33, 95% confidence interval: upper 26,
lower 1.54, p < 0.05; sensitivity 76%, specificity 66.7%, accuracy 72.5%, positive predictive
level 79.2%, negative predictive level 62.5%, p < 0.01). In conclusion, significant increasester and Division of Hepatobiliary Medicine, Department of Internal Medicine, Kaohsiung Medical
Road, Kaohsiung 807, Taiwan.
om.tw (Z.-Y. Lin).
vier Taiwan LLC. All rights reserved.
VEGF-A in HCC patients treated by TACE 315of serum level VEGF-A and angiopoietin-2 after TACE have been demonstrated from this study.
Therefore, serial VEGF-A level 1 day before and 7 days after TACE may be used to predict rapid
HCC growth.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) is a hypervascular tumor
characterized by neovascularization. The vascular endo-
thelial growth factor (VEGF) and angiopoietin families have
been found to work in tandem with HCC angiogenesis [1].
The VEGF family has at least seven members, and VEGF-A is
a key player in angiogenesis [2,3]. VEGF mRNA is usually
significantly upregulated in HCC [4e10]. Increased serum or
plasma VEGF levels have been shown to be correlated with
microscopic venous invasion [11], distant metastasis [12],
and overall survival in HCC [13e15]. Although there were
some conflicting results [16], other studies showed that
preoperative serum VEGF [17], circulating VEGF-A mRNA
[18], or expression of VEGF-A mRNA in HCC tissue [19] play
an important role in the prediction of postoperative
recurrence of HCC. Moreover, high expression of VEGF-A
mRNA in noncancerous liver remnants of HCC may be
a significant biological indicator for the invasiveness of
postoperative recurrence [20]. Angiopoietins have been
identified as ligands for Tie-2 receptor and are thought to
be important factors in vascular maturation and stability
during angiogenesis [1,3]. Levels of angiopoietin-2 mRNA
expressions in HCC [7], nonesmall cell lung cancer [21], and
gastric cancer [22,23] have been reported to be signifi-
cantly increased compared with adjacent noncancerous
components. This increased expression may play a critical
role in promoting tumor angiogenesis and progression
[7,21,23]. High serum angiopoietin-2 levels have been
shown to correlate with tumor invasion in esophageal
squamous cell cancer [24] and recurrence of lung cancer
[25]. Endostatin, the 20-kDa C-terminal fragment of
collagen XVIII [26], is an angiogenic inhibitor [27] and has
been shown to prevent angiogenesis and drive large tumors
into dormancy [28]. Endostatin expressions are significantly
stronger in adjacent nontumorous tissues than in HCC
tissue, and the expressions in nontumorous tissues corre-
late with HCC stages and expressions of VEGF [29]. Serum
endostatin is found to have a significantly inverse correla-
tion with the angiogenic score of HCC [30]. However, it is
still controversial that endostatin expression or its serum
level has a significant role in predicting the prognosis of
patients with HCC [13,29e31].
Transcatheter arterial chemoembolization (TACE) is
a palliative method for the management of HCC [32e36].
This procedure induces extensive ischemic necrosis in HCC.
Ischemia strongly correlates with increased expression of
angiogenic factors and stimulates angiogenesis. TACE can
also increase VEGF expression in the residual surviving HCC
tissues [37]. Li et al. [38] showed that plasma VEGF levels
were significantly elevated in patients with HCC on the first
post-TACE day. Then VEGF levels decreased gradually on
the third day and had no statistical difference with pre-
TACE levels on the seventh day post-TACE. This indicates
that persistent elevation of VEGF level 7 days after TACEmay be of clinical significance. On the other hand, the
possible influence of TACE on serum angiopoietin-2 and
endostatin levels has not been clarified. This prospective
study was to investigate the potential utilities of serial
serum VEGF-A, angiopoietin-2, and endostatin level 1 day
before and 7 days after TACE in cirrhotic patients with HCC.
Patients and methods
Patients
A total of 40 cirrhotic patients with newly discovered HCC
planned to receive the first session of TACE were included
(Table 1). Two patients with chronic hepatitis B infection
started lamivudine therapy 2 months after TACE because of
persistently elevated serum alanine aminotransferase (ALT,
normal upper limit 40 IU/L) levels more than five times of
normal upper limit. No patient with chronic hepatitis C
infection received combined interferon and ribavirin
therapy during the study periods. The diagnosis of HCC was
based on fine-needle aspiration cytology and/or biopsy.
HCC staging was based on the American Joint Committee on
Cancer TNM staging system [39]. The reasons for 14 patients
with HCC staging I to receive TACE rather than operative
resection or local ablation therapy were because of larger
tumor sizes (>5 cm) and ages >70 years in three patients
and the larger tumor (5 cm) located near hepatic hilum in
two patients. For the remaining nine patients with HCC
staging I, the decisions to receive TACE alone were made by
the patients after being informed the risks and benefits of
TACE, operative resection, and local ablation therapy. The
diagnosis of liver cirrhosis was based on a coarse and con-
tracted liver on abdominal ultrasonography with at least
one of the following two positive findings including (1)
esophageal or cardiac varices found by endoscopic exami-
nation and (2) the presence of portal collateral circulation
with or without splenomegaly on computed tomography.
Chronic hepatitis B or C was diagnosed by persistently
positive serum hepatitis B surface antigen or antihepatitis C
antibody for more than 6 months. The etiology of cirrhosis
and HCC was considered to be alcoholic in origin when
patients had a history of alcohol consumption for more than
120 g alcohol per day for more than 10 years and no other
known causes of chronic hepatitis. Child-Pugh classification
was applied to record the hepatic reserved function. This
study was approved by the institutional review board of our
hospital (ClinicalTrials.gov NCT00834028). Each patient was
given informed consent to participate in this study.
Methods
All patients received serum VEGF-A, angiopoietin-2, and
endostatin measurements and complete blood count 1 day
before and 7 days after TACE. The liver function test and
Table 1 Characteristics of 40 cirrhotic patients with
newly discovered HCC planned to receive the first session of
transcatheter arterial chemoembolization
Characteristics Child-Pugh
Class A
Child-Pugh
Class B
Total
No. of patients 33 7 40
Sex (male/female)a 28/5 7/0 35/5
Age (yr)a 63, 44e77 57, 51e68 63, 44e77
Etiologya
Chronic hepatitis B 17 4 21
Chronic hepatitis C 12 3 15
Alcohol 2 0 2
Unknown 2 0 2
HCC staginga
I 14 0 14
II 9 3 12
IIIA 6 1 7
IIIC 3 2 5
IV 1 1 2
a A p value >0.05.
Data are given as the median and range. HCC staging is based on
the American Joint Committee on Cancer TNM staging system.
The Wilcoxon rank sum test, Fisher exact test, or Chi-square
test was applied for statistical analysis.
HCC Z hepatocellular carcinoma.
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concomitantly performed. Data obtained 7 days after TACE
minus data obtained before TACE were used to calculate
the differences of data in serial comparisons.
TACE was carried out by infusion of the mixture of
chemotherapeutic agents (epirubicin; Pharmacia & Upjohn
S.p.A, Milan, Italy, with or without mitomycin-C; Kyowa
Hakko Kogyo Co., Ltd, Tokyo, Japan) and lipiodol (Lipiodol
Ultra-Fluid; Guerbet, Aulnay-sous-Bois, France) into the
lesion, followed by the embolization of the supplying
arteries using various sizes of nonabsorbable Embosphere
Microspheres (BioSphere Medical, Inc., Rockland, MA, USA)
or absorbable agents (Avitene Microfibrillar Collagen
Hemostat; MedChem Products, Inc., Woburn, MA, USA, or
gelfoam particles of 1e2 mm in size, Pharmacia & Upjohn
Company, Kalamazoo, MI, USA). The doses of chemothera-
peutic agents and the amount of lipiodol depended on the
size of the tumor. The choice of using nonabsorbable or
absorbable embolic agent depended on the sizes and
patterns of the supplying arteries. The procedure of TACE
was completed when all detectable supplying arteries of
the tumor and arterioportal shunt were embolized as
detected by immediate post-TACE angiography. The whole
procedure of TACE was carried out by an independent
radiologist who did not know the contents of the study. All
patients were followed for 3 months. The liver function test
and serum AFP measurement were performed at an interval
of 1 month, abdominal ultrasonography was performed 2e3
months after TACE, chest X-ray and computed tomography
or magnetic resonance imaging were performed 3 months
after TACE. Angiography was performed when evidence ofintrahepatic recurrence of HCC existed. The results of TACE
were classified into rapid growth and without rapid growth
of HCC after TACE in 2 groups. Rapid growth of HCC was
defined as increase of tumor size >1 cm and/or develop-
ment of intrahepatic or metastatic nodule, which was not
detected on previous imaging studies.
All patients fasted overnight for blood sampling. The
serum used for the study was collected by centrifugation of
blood immediately withdrawn from the patient and stored at
20C for further investigation. Serum levels of VEGF-A,
angiopoietin-2, and endostatinwere determined by enzyme-
linked immunosorbent assay (VEGF-A; IBL-Hamburg,
Hamburg, Germany and angiopoietein-2, endostatin; Glob-
alSpec, Inc., New York, NY, USA). The experimental proce-
dures were carried out following the manufacturer’s
protocols. The detection limit for VEGF-A using this method
was 32 pg/mL. The level below 32 pg/mL was defined as
undetectable. The level of 32 pg/mL was used in patients
with undetectable serum VEGF-A level for statistical calcu-
lation. The detection limits for angiopoietin-2 and endo-
statin were 8.29 pg/mL and 0.023 ng/mL, respectively.
Statistical analysis
Data were analyzed using JMP 7.0 software (SAS Institute,
Cary, NC, USA). All data for continuous variables were
expressed as median and range. The Wilcoxon rank sum test
was used to compare the difference between medians of
continuous variables. Because there were large variations
in platelet counts and VEGF-A, angiopoietin-2, endostatin,
and ALT levels among patients, the nonparametric two-
sided sign test rather than the paired t test was used for the
comparison of paired medians. The Fisher exact test or Chi-
square test was used to compare proportions between
groups. Correlation analysis was investigated by the
calculation of a correlation coefficient (r). A receiver
operating characteristic curve was used to establish the
cutoff level that provided the maximal diagnostic accuracy.
Stepwise logistic regression was used for multivariate
analysis. The statistical significance was defined as
p < 0.05.
Results
Data before TACE
There was no significant correlation among VEGF-A,
angiopoietin-2, endostatin, AFP, and ALT levels.
VEGF-A
Patients with HCC staging >II showed higher VEGF-A level
than patients with HCC staging II (88.74 pg/mL,
32e751.9 pg/mL vs. 32 pg/mL, 32e1535.64 pg/mL,
p < 0.05). This level did not show significant difference
between Child-Pugh Class A and B. Twenty patients showed
undetectable VEGF-A, and the remaining 20 patients
showed detectable VEGF-A levels (Table 2). Patients with
detectable VEGF-A levels had significantly higher propor-
tion of HCC staging >II and higher angiopoietin-2 levels
Table 2 Comparison between patients with and without detectable serum vascular endothelial growth factor-A levels before
transcatheter arterial chemoembolization
Detectable (n Z 20) Undetectable (n Z 20) p
Age (yr) 62.5, 44e77 64, 53e76 >0.05
Sex (male/female) 18/2 17/3 >0.05
Child-Pugh Class (A/B) 15/5 18/2 >0.05
HCC staging (II/>II) 10/10 16/4 <0.05
Angiopoietin-2 (pg/mL) 4974.6, 3301.9e9413.6 3921.9, 3041.6e6717.4 <0.05
Endostatin (ng/mL) 170.74, 139.94e213.36 164.59, 132.53e276.67 >0.05
AFP (ng/mL) 21.8, 3.2e8529.1 19.95, 1.05e1.502 >0.05
ALT (IU/L) 50, 14e186 42.5, 18e176 >0.05
Platelet counts (103/mL) 135.5, 52e282 113.5, 53e235 >0.05
Data are given as the median and range. HCC staging is based on the American Joint Committee on Cancer TNM staging system. The
Wilcoxon rank sum test, Fisher exact test, or Chi-square test was applied for statistical analysis. The normal ranges for platelet counts
were 172e450  103/mL.
AFP Z alpha-fetoprotein (normal upper limit 20 ng/mL); ALT Z alanine aminotransferase (normal upper limit 40 IU/L);
HCC Z hepatocellular carcinoma.
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levels did not show significant correlation with platelet
counts and age.
Angiopoietin-2
Patients with HCC staging >II showed significantly higher
angiopoietin-2 levels than patients with HCC staging II
(5326.3 pg/mL, 3301.9e9413.6 pg/mL vs. 3983.35 pg/mL,
3041.6e6717.4 pg/mL, p < 0.05). Patients with Child-Pugh
Class B showed higher angiopoietin-2 levels than those with
Child-Pugh Class A (6651.5 pg/mL, 3640.5e9413.6 pg/mL
vs. 3981.1 pg/mL, 3041.6e6576.2 pg/mL, p < 0.01).
Angiopoietin-2 levels did not show significant correlation
with platelet counts and age.
Endostatin
Endostatin levels did not show significant difference
between patients with HCC staging II and >II and between
patients with Child-Pugh Class A and B. Endostatin levels
showed significant correlation with platelet counts in all
patients (r Z 0.38, p < 0.05), in patients with Child-Pugh
Class A (r Z 0.44, p < 0.05), and in Child-Pugh Class A
patients with undetectable VEGF-A (r Z 0.74, p < 0.001).
Endostatin levels also showed significant correlation withTable 3 Changes of data after transcatheter arterial chemoem
Increase
VEGF-A (pg/mL) 25 (59.2, 14.1e230.7)
Angiopoietin-2 (pg/mL) 29 (606.1, 59e17643.3)
Endostatin (ng/mL) 22 (11.65, 0.23e42.88)
ALT (IU/L) 35 (106, 1e485)
Platelet counts (103/mL) 4 (2, 1e6)
Parentheses indicate median and range of changed data. The nonpar
ALT Z alanine aminotransferase; VEGF Z vascular endothelial growtage in patients with Child-Pugh Class A (rZ 0.36, p < 0.05)
and in Child-Pugh Class A patients with detectable VEGF-A
levels (r Z 0.61, p < 0.05).
Alterations of data after TACE
TACE caused significant increases of VEGF-A, angiopoietin-
2, and ALT levels and significant decrease of platelet counts
(Table 3). There was no significant correlation between
differences of ALT levels and differences of platelet counts.
VEGF-A
Eighteen patients with detectable VEGF-A levels before
TACE and seven patients with undetectable VEGF-A levels
before TACE showed increased VEGF-A levels after TACE.
Patients with detectable VEGF-A levels before TACE had
higher incidence of increased VEGF-A levels after TACE (18
of 20) than patients with undetectable VEGF-A levels
before TACE (7 of 20) (p < 0.01). Differences of VEGF-A
levels showed negative correlation with differences of ALT
levels in all patients (r Z 0.34, p < 0.05) and in patients
with Child-Pugh Class A (r Z 0.42, p < 0.05). Differences
of VEGF-A levels showed negative correlation with differ-
ences of platelet counts in all patients (rZ0.5, pZ 0.001)
and in patients with Child-Pugh Class B (rZ 0.9, p< 0.01),bolization in 40 patients
Decrease No change p
2 (6.08, 4.3e7.86) 13 <0.01
11 (298.7, 13.8e942) 0 0.01
18 (6.55, 0.12e51.02) 0 >0.1
5 (9, 8e30) 0 <0.01
36 (24, 1e154) 0 <0.01
ametric two-sided sign test was used for statistical analysis.
h factor.
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Differences of VEGF-A levels had positive correlation with
differences of angiopoietin-2 levels in all patients (rZ 0.59,
p< 0.0001) and in patients with Child-Pugh Class A (rZ 0.35,
p < 0.05) or B (rZ 0.86, p < 0.05).
Angiopoietin-2
There was no significant correlation between differences of
angiopoietin-2 levels and differences of ALT levels. Differ-
ences of angiopoietin-2 levels showed negative correlation
with differences of platelet counts in all patients
(r Z 0.7, p < 0.0001) and in patients with Child-Pugh
Class B (r Z 0.99, p < 0.0001), but not in patients with
Child-Pugh Class A (p > 0.05).
Endostatin
Differences of endostatin levels showed positive correlation
with differences of ALT levels in all patients (r Z 0.33,
p < 0.05) and in patients with Child-Pugh Class A (rZ 0.37,
p < 0.05). There was no significant correlation between
differences of endostatin levels and differences of platelet
counts.
Follow-up
Twenty-five patients showed rapid growth of HCC within 3
months after TACE (Table 4) (Fig. 1AeC). Patients with
rapid growth of HCC had significantly higher proportion ofTable 4 Comparison between patients with and without rapid
Rapid growth of HCC (þ) (n Z
Age (yr) 65, 44e77
Sex (male/female) 22/3
Child-Pugh Class (A/B) 20/5
HCC staging (II/>II) 13/12
Data before TACE
VEGF-A (pg/mL) 57.79, 32e1535.64
Angiopoietin-2 (pg/mL) 4209.2, 3104.3e9413.6
Endostatin (ng/mL) 167.04, 137.7e276.67
AFP (ng/mL) 32.5, 1.05e8529.1
ALT (IU/L) 47, 14e171
Platelet counts (103/mL) 135, 52e282
Differences of data caused by TACE
VEGF-A (pg/mL) 43.21, 230.7(0)
Angiopoietin-2 (pg/mL) 391.4, 17643.3(942)
Endostatin (ng/mL) 2.14, 23.26(51.02)
ALT (IU/L) 89, 314(8)
Platelet counts (103/mL) 26, 2(154)
Data are given as the median and range. HCC staging is based on the A
obtained before TACE minus the data obtained 3 days after TACE were
The Wilcoxon rank sum test, Fisher exact test, or Chi-square test wa
counts were 172e450  103/mL.
AFP Z alpha-fetoprotein (normal upper limit 20 ng/mL); ALT
HCC Z hepatocellular carcinoma; TACE Z transcatheter arterial cheHCC staging >II and higher increment of VEGF-A levels after
TACE than patients without rapid growth of HCC. There was
only marginally significant difference of post-TACE VEGF-A
levels between patients with and without rapid growth of
HCC (127.6 pg/mL, 32e1628.86 pg/mL vs. 46.1 pg/mL,
32e485.29 pg/mL, p Z 0.057). Difference of ALT levels or
platelet counts caused by TACE did not showed significant
difference between patients with and without rapid growth
of HCC (89 IU/L, 314 to 8 IU/L vs. 106 IU/L, 485 to 30 IU/
L, p > 0.05 for ALT; 26  103/mL, 2 to 154  103/mL vs.
20  103/mL, 6 to 48  103/mL, p > 0.05 for platelet
counts). Stepwise logistic regression analysis using statis-
tical significantly items in Table 4, includes (1) increase of
VEGF-A level >16.7 pg/mL selected by receiver operating
characteristic curve (Fig. 2) and (2) HCC staging >II as
variables showed that only increase of VEGF-A level
>16.7 pg/mL was an independent predictor for rapid
growth of HCC (odds ratio 6.33, 95% confidence interval:
upper 26, lower 1.54, p < 0.05; sensitivity 76%, specificity
66.7%, accuracy 72.5%, positive predictive level 79.2%,
negative predictive level 62.5%, p < 0.01).Discussion
The biologically active VEGF may be stored in platelet to
prevent circulating VEGF from inducing the development of
new blood vessels except at sites where coagulation takes
place [40]. Application of serum rather than plasma
samples to measure VEGF-A levels can be influenced by
release of VEGF-A from destructed platelets during thegrowth of HCC after TACE
25) Rapid growth of HCC () (n Z 15) p
63, 55e76 >0.05
13/2 >0.05
13/2 >0.05
13/2 <0.05
32, 32e493.14 >0.05
4337.3, 3041.6e6651.5 >0.05
170.3, 132.53e227.04 >0.05
14.1, 3.2e1022.7 >0.05
44, 19e186 >0.05
118, 53e233 >0.05
0, 107.1(7.857) <0.05
248.4, 1055.9(637.9) >0.05
2.22, 42.88(9.85) >0.05
106, 485(30) >0.05
20, 6(48) >0.05
merican Joint Committee on Cancer TNM staging system. The data
used to calculate the differences of data in serial determinations.
s applied for statistical analysis. The normal ranges for platelet
Z alanine aminotransferase (normal upper limit 40 IU/L);
moembolization; VEGF Z vascular endothelial growth factor.
Figure 1. (AeC) Comparison of the differences of VEGF-A
(1A), angiopoietin-2 (1B), and endostatin (1C) levels between
patients with and without rapid growth of hepatocellular
carcinoma. There was a significant difference in VEGF-A levels
(p < 0.05). Data obtained 7 days after transcatheter arterial
chemoembolization minus data obtained before transcatheter
arterial chemoembolization were used to calculate the
differences of data in serial determinations. VEGF-
A Z vascular endothelial growth factor-A.
Figure 2. A receiver operating characteristic curve was used
to establish the cutoff level of increased vascular endothelial
growth factor-A level 7 days after transcatheter arterial che-
moembolization to predict rapid growth of hepatocellular
carcinoma within 3 months after transcatheter arterial che-
moembolization with maximal diagnostic accuracy (p < 0.05).
VEGF-A in HCC patients treated by TACE 319collection of sample. This implies that the results of serum
VEGF-A measurements can be influenced by platelet
counts. Despite these potential pitfalls in serum VEGF-A
measurement, previous studies showed that serum VEGF
levels appeared to have significant predictive power for
estimating overall survival in HCC and might be useful for
defining prognosis in HCC [11,13e15]. This may be because
of significantly strong correlation between serum and
plasma VEGF levels [41]. Moreover, only measurement of
serum rather than plasma VEGF-A levels can reflect the
total amount of VEGF-A produced by the patient. There-
fore, serum VEGF-A levels were adopted for analysis in the
present study.
These results were in concordant with the previous
studies that patients with more advanced HCC had higher
serum VEGF levels [11,13e15] and also higher serum
angiopoietin-2 levels compared with the patients with lessadvanced HCC. Although VEGF and angiopoietin-2 have
been found to work cooperatively [1], our results did not
reveal significant correlation between serum VEGF-A and
angiopoietin-2 levels before TACE. This might be deduced
from the present research that showed no significant
difference of VEGF-A levels between patients with Child-
Pugh Class A and B. On the contrary, high serum angio-
poietin-2 levels were more frequently observed in patients
with Child-Pugh Class B than in patients with Child-Pugh
Class A. No correlation between serum VEGF-A levels and
platelet counts may be because of half of our patients with
undetectable VEGF-A levels before TACE. On the other
hand, our results did not show significant association
between serum endostatin levels and HCC staging. This
result was in accordance with two previous studies [13,31],
but different from one study [30]. This can be explained by
that the serum endostatin levels are influenced by some
confounding factors such as age, platelet counts, and serum
VEGF-A levels of the patients as demonstrated in the
present study.
Increase of serum ALT levels after TACE may partially
reflect the damage of HCC and probably the adjacent
nontumorous part of the liver caused by this procedure.
Increase of ALT levels after TACE was found to correlate
with decrease of VEGF-A levels and increase of endostatin
levels. This implies that increase of tumor destruction by
TACE decreases VEGF-A production from tumor, and
increase of tissue damage may stimulate endostatin
production. However, TACE did not cause significant
difference in changes of serum endostatin levels. Different
degrees of tissue damage caused by TACE among different
patients may be the explanation. On the other hand, the
present study showed that TACE actually caused significant
increase rather than decrease of VEGF-A levels. This result
was similar to the previous studies [42,43]. Increase of
VEGF expression in the residual HCC tissues because of
320 M.-Y. Hsieh et al.TACE-induced ischemia may be the main explanation [37].
Negative correlation between differences of VEGF-A levels
and differences of platelet counts suggests that release of
VEGF-A from destructed platelets caused by TACE may be
an another explanation. Although the possible influence of
TACE on serum angiopoietin-2 levels has not been clarified,
the present results also showed increased angiopoietin-2
levels after TACE. Because there was also a negative
correlation between differences of angiopoietin-2 levels
and differences of platelet counts, TACE-induced ischemia
and release of angiopoietin-2 from destructed platelets
caused by TACE may be explanations.
The American Joint Committee on Cancer TNM staging
system used in the present study was reported to provide
the most effective means of assessing the prognosis of
patients after curative resection of HCC [44]. However, our
results did not show that TNM HCC staging was an inde-
pendent predictor for rapid growth of HCC after TACE. The
major reason is that all HCC staging systems can only be
used to estimate the degree of tumor invasion at the time
of discovery. Patients with higher HCC staging having worse
prognosis than patients with lower HCC staging is because
of no satisfactory treatment for patients with higher HCC
staging. These staging systems are not used to predict the
speed of tumor growth. The characteristics of residual
cancer cells after treatment and the presence of stimu-
lating or inhibiting factors of the patient are major deter-
minants for rapid growth of HCC after TACE. Patients with
slow growing cancer cells do show slow growth of HCC after
TACE regardless of the effects of TACE unless the charac-
teristics of cancer cells are changed caused by TACE.
Therefore, the present study did not choose items such as
size of tumors, number of tumors, vascular invasion, and
technique for TACE to predict rapid growth of HCC.
Increase of serum VEGF levels after TACE can directly
promote angiogenesis in the residual HCC tissue [37,38].
Although the present study showed that patients with
detectable serum VEGF-A levels before TACE had higher
incidence of increased serum VEGF-A levels after TACE than
patients without detectable VEGF-A levels, there was no
significant cutoff serum VEGF-A level before TACE to
predict rapid growth of HCC after TACE. This is caused by
the influence of diverse effects of TACE on different
patients with HCC. Shim and et al. [43] showed that the
related change in serum VEGF/platelet counts ratio 1e2
days after TACE from baseline >0.5 was significantly
correlated with newly developed extrahepatic metastases 1
and 6 months after TACE. It is demonstrated that negative
correlation between differences of platelet counts and
differences of VEGF-A or angiopoietin-2 levels caused by
TACE mainly originated from Child-Pugh Class B but not
from Child-Pugh Class A. This implies using platelet counts
to correct for VEGF levels may be affected by Child-Pugh
class. Therefore, we adopt another method to predict rapid
growth of HCC after TACE. The serum or plasma VEGF levels
1e2 days after TACE in most patients are elevated
[38,42,43]. Because VEGF can be stored in circulating
platelets, which have life span of around 3 days,
measurement of total VEGF production within 5 days after
TACE should theoretically consider the influence by the
platelet counts. The influence of TACE-induced ischemia on
VEGF production will subside around 7 days after TACE [38].This implies that measurement of serum VEGF-A level 7
days after TACE alone may be used to reflect the charac-
teristics of residual cancer cells in the production of VEGF-
A. However, the results showed that the range of VEGF-A
levels before TACE was quite wide. Decreased post-TACE
VEGF-A levels in patients with high pre-TACE levels may still
be higher than increased post-TACE VEGF-A levels in
patients with low pre-TACE levels. Therefore, measure-
ment of serum VEGF-A level 7 days after TACE alone cannot
actually reflect the influence of TACE on the production of
VEGF-A from the residual cancer cells. On the contrary,
comparison between serum VEGF-A levels before and 7 days
after TACE can attenuate the impact from variations in
baseline VEGF-A levels and reflect the influence of TACE on
the production of VEGF-A from the residual cancer cells.
Patients with remarkable increase of serum VEGF-A levels 7
days after TACE have risk of rapid growth of HCC after TACE
and should be closely followed.
The present results failed to show difference of angio-
poietin-2 as predictor for rapid growth of HCC within 3
months after TACE. Small number of patients in the present
study may be one of the reasons. Because patients with
Child-Pugh Class B had significantly higher angiopoietin-2
levels than patients with Child-Pugh Class A, influence of
different degrees of Child-Pugh classification among
patients may be another reason. Further study may be
necessary to clarify this issue.
In conclusion, the present results indicate that TACE
causes significant increases of serum VEGF-A and angio-
poietin-2 levels. The pattern of change in endostatin was
not significantly influenced by TACE. Serial serum VEGF-A
measurements 1 day before and 7 days after TACE may have
potential to predict rapid growth of HCC after TACE.Acknowledgment
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